多能蛋白聚糖在恶性肿瘤中的表达及生物学作用的研究进展

doi:10.3969/j.issn.1674-8115.2024.04.014

摘要/Abstract

摘要：

恶性肿瘤严重威胁着人类健康，是全球人类死亡的主要原因之一。为了进一步提高对于恶性肿瘤的治疗效果，延长患者生存时间，明确恶性肿瘤的发病机制以及寻找新的诊断和治疗靶点变得尤为重要。研究发现，恶性肿瘤的发生发展是肿瘤细胞与肿瘤微环境（tumor microenvironment，TME）相互作用的结果。多能蛋白聚糖（versican）是一种硫酸软骨素蛋白聚糖，属于外源凝集素蛋白聚糖家族，由VCAN基因编码，是细胞外基质的主要成分，在胚胎发育和炎症反应过程中均发挥重要作用。作为TME的重要组成部分，versican在肾细胞癌、肝细胞癌、胃癌等多种肿瘤组织中异常表达，且与患者的临床病理特征及预后密切相关，是肿瘤早期诊断和预后评估的潜在生物标志物。进一步的研究显示，versican可通过促进肿瘤细胞增殖、侵袭和转移，抑制肿瘤细胞凋亡，促进肿瘤血管生成和抑制抗肿瘤免疫反应等多种方式促进肿瘤的发展。该文就versican在恶性肿瘤中的表达及生物学作用的研究现状进行综述，旨在为肿瘤的后续研究及临床诊治提供参考依据。

关键词: 多能蛋白聚糖, 恶性肿瘤, 肿瘤微环境, 细胞外基质

Abstract:

Malignant tumors pose a serious threat to human health and are one of the main causes of human death worldwide. In order to further improve the therapeutic outcomes of malignant tumors and prolong patients' survival time, clarifying the pathogenesis of malignant tumors and searching for new diagnostic and therapeutic targets become particularly important. It has been found that the occurrence and development of malignant tumors are the results of the interaction between tumor cells and the tumor microenvironment (TME). Versican, encoded by the VCAN gene, is a type of chondroitin sulfate proteoglycan belonging to the exogenous lectin proteoglycan family. It is a major component of the extracellular matrix and plays an important role in embryonic development and inflammatory responses. As an important component of TME, versican is abnormally expressed in various tumor tissues such as renal cell carcinoma, hepatocellular carcinoma, and gastric cancer, and is closely related to the clinical pathological characteristics and prognosis of the patients. It is a potential biomarker for early diagnosis and prognostic evaluation of tumors. Further researches have shown that versican can promote tumor development in a number of ways, such as promoting tumor cell proliferation, invasion and metastasis, inhibiting tumor cell apoptosis, promoting tumor angiogenesis, and inhibiting anti-tumor immune responses. This article reviews the current research status of the expression and biological effects of versican in malignant tumors, aiming to provide reference for subsequent research, clinical diagnosis and treatment of tumors.

Key words: versican, malignant tumor, tumor microenvironment, extracellular matrix

中图分类号:

R730.2

刘林楠, 冯莉, 王龙, 刘嘉寅, 范志松. 多能蛋白聚糖在恶性肿瘤中的表达及生物学作用的研究进展[J]. 上海交通大学学报（医学版）, 2024, 44(4): 525-530.

LIU Linnan, FENG Li, WANG Long, LIU Jiayin, FAN Zhisong. Research progress in the expression of versican in malignant tumors and its biological roles[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(4): 525-530.

图/表 1

参考文献 55

1	ISLAMI F, WARD E M, SUNG H, et al. Annual report to the nation on the status of cancer, part 1: national cancer statistics[J]. J Natl Cancer Inst, 2021, 113(12): 1648-1669.
2	CHEVRIER S, LEVINE J H, ZANOTELLI V R T, et al. An immune atlas of clear cell renal cell carcinoma[J]. Cell, 2017, 169(4): 736-749.e18.
3	KARAGIORGOU Z, FOUNTAS P N, MANOU D, et al. Proteoglycans determine the dynamic landscape of EMT and cancer cell stemness[J]. Cancers, 2022, 14(21): 5328.
4	KESH K, GUPTA V K, DURDEN B, et al. Therapy resistance, cancer stem cells and ECM in cancer: the matrix reloaded[J]. Cancers, 2020, 12(10): 3067.
5	HIRANI P, GAUTHIER V, ALLEN C E, et al. Targeting versican as a potential immunotherapeutic strategy in the treatment of cancer[J]. Front Oncol, 2021, 11: 712807.
6	MITSUI Y, SHIINA H, KATO T, et al. Versican promotes tumor progression, metastasis and predicts poor prognosis in renal carcinoma[J]. Mol Cancer Res, 2017, 15(7): 884-895.
7	吕磊, 郑福鑫, 周高峰, 等. 多功能蛋白聚糖基因对膀胱尿路上皮癌免疫浸润及预后的影响[J]. 解放军医学杂志, 2023, 48(8): 921-928.
	LÜ L, ZHENG F X, ZHOU G F, et al. Effect of VCAN on immune infiltration and prognosis of bladder urothelial carcinoma[J]. Medical Journal of Chinese People's Liberation Army, 2023, 48(8): 921-928.
8	SUN G S, ZHENG W B, TAN P Y, et al. Comprehensive analysis of VCAN expression profiles and prognostic values in HCC[J]. Front Genet, 2022, 13: 900306.
9	KATO K, FUKAI M, HATANAKA K C, et al. Versican secreted by cancer-associated fibroblasts is a poor prognostic factor in hepatocellular carcinoma[J]. Ann Surg Oncol, 2022, 29(11): 7135-7146.
10	WANG M Q, LI Y P, XU M, et al. VCAN, expressed highly in hepatitis B virus-induced hepatocellular carcinoma, is a potential biomarker for immune checkpoint inhibitors[J]. World J Gastrointest Oncol, 2022, 14(10): 1933-1948.
11	DE WIT M, CARVALHO B, DELIS-VAN DIEMEN P M, et al. Lumican and versican protein expression are associated with colorectal adenoma-to-carcinoma progression[J]. PLoS One, 2017, 12(5): e0174768.
12	GUO J, LIU Y. INHBA promotes the proliferation, migration and invasion of colon cancer cells through the upregulation of VCAN[J]. J Int Med Res, 2021, 49(6): 3000605211014998.
13	WANG L, FENG L, LIU L N, et al. Joint effect of THBS2 and VCAN accelerating the poor prognosis of gastric cancer[J]. Aging, 2023, 15(5): 1343-1357.
14	SONG J Q, WEI R Y, HUO S Y, et al. Versican enrichment predicts poor prognosis and response to adjuvant therapy and immunotherapy in gastric cancer[J]. Front Immunol, 2022, 13: 960570.
15	ZHAI L L, CHEN W J, CUI B S, et al. Overexpressed versican promoted cell multiplication, migration and invasion in gastric cancer[J]. Tissue Cell, 2021, 73: 101611.
16	CHENG Y, SUN H Z, WU L L, et al. VUp-regulation of VCAN promotes the proliferation, invasion and migration and serves as a biomarker in gastric cancer[J]. Onco Targets Ther, 2020, 13: 8665-8675.
17	PAPADAS A, ARAUZ G, CICALA A, et al. Versican and versican-matrikines in cancer progression, inflammation, and immunity[J]. J Histochem Cytochem, 2020, 68(12): 871-885.
18	WU Y J, LA PIERRE D P, WU J, et al. The interaction of versican with its binding partners[J]. Cell Res, 2005, 15(7): 483-494.
19	PAPADAS A, ASIMAKOPOULOS F. Versican in the tumor microenvironment[J]. Adv Exp Med Biol, 2020, 1272: 55-72.
20	KERN C B, NORRIS R A, THOMPSON R P, et al. Versican proteolysis mediates myocardial regression during outflow tract development[J]. Dev Dyn, 2007, 236(3): 671-683.
21	HAYES A, SUGAHARA K, FARRUGIA B, et al. Biodiversity of CS-proteoglycan sulphation motifs: chemical messenger recognition modules with roles in information transfer, control of cellular behaviour and tissue morphogenesis[J]. Biochem J, 2018, 475(3): 587-620.
22	KAMIYA N, WATANABE H, HABUCHI H, et al. Versican/PG-M regulates chondrogenesis as an extracellular matrix molecule crucial for mesenchymal condensation[J]. J Biol Chem, 2006, 281(4): 2390-2400.
23	FENG J, LI Y D, LI Y, et al. Versican promotes cardiomyocyte proliferation and cardiac repair[J]. Circulation, 2024, 149(13): 1004-1015.
24	WIGHT T N, KANG I, MERRILEES M J. Versican and the control of inflammation[J]. Matrix Biol, 2014, 35: 152-161.
25	MATSUMOTO K, SHIONYU M, GO M, et al. Distinct interaction of versican/PG-M with hyaluronan and link protein[J]. J Biol Chem, 2003, 278(42): 41205-41212.
26	DAY A J, MILNER C M. TSG-6: a multifunctional protein with anti-inflammatory and tissue-protective properties[J]. Matrix Biol, 2019, 78-79: 60-83.
27	WIGHT T N, KANG I, EVANKO S P, et al. Versican: a critical extracellular matrix regulator of immunity and inflammation[J]. Front Immunol, 2020, 11: 512.
28	TOCCHI A, PARKS W C. Functional interactions between matrix metalloproteinases and glycosaminoglycans[J]. FEBS J, 2013, 280(10): 2332-2341.
29	KANG I, HARTEN I A, CHANG M Y, et al. Versican deficiency significantly reduces lung inflammatory response induced by polyinosine-polycytidylic acid stimulation[J]. J Biol Chem, 2017, 292(1): 51-63.
30	DUTT S, KLÉBER M, MATASCI M, et al. Versican V0 and V1 guide migratory neural crest cells[J]. J Biol Chem, 2006, 281(17): 12123-12131.
31	WU Y J, SHENG W, CHEN L W, et al. Versican V1 isoform induces neuronal differentiation and promotes neurite outgrowth[J]. Mol Biol Cell, 2004, 15(5): 2093-2104.
32	MERRILEES M J, BEAUMONT B W, BRAUN K R, et al. Neointima formed by arterial smooth muscle cells expressing versican variant V3 is resistant to lipid and macrophage accumulation[J]. Arterioscler Thromb Vasc Biol, 2011, 31(6): 1309-1316.
33	KANG I, YOON D W, BRAUN K R, et al. Expression of versican V3 by arterial smooth muscle cells alters tumor growth factor β (TGFβ)-, epidermal growth factor (EGF)-, and nuclear factor κB (NFκB)-dependent signaling pathways, creating a microenvironment that resists monocyte adhesion[J]. J Biol Chem, 2014, 289(22): 15393-15404.
34	KISCHEL P, WALTREGNY D, DUMONT B, et al. Versican overexpression in human breast cancer lesions: known and new isoforms for stromal tumor targeting[J]. Int J Cancer, 2010, 126(3): 640-650.
35	ZHANGYUAN G Y, WANG F, ZHANG H T, et al. VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway[J]. Oncogene, 2020, 39(6): 1213-1230.
36	TAN R Y, ZHANG G H, LIU R C, et al. Identification of early diagnostic and prognostic biomarkers via WGCNA in stomach adenocarcinoma[J]. Front Oncol, 2021, 11: 636461.
37	陆思芬, 魏小珍, 牟必琴, 等. 基于生物信息数据探究VCAN在食管鳞状细胞癌预后中的作用[J]. 中国胸心血管外科临床杂志, 2022, 29(8): 1031-1041.
	LU S F, WEI X Z, MOU B Q, et al. Exploring the role of VCAN in the prognosis of esophageal squamous cell carcinoma based on bioinformatics data[J]. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2022, 29(8): 1031-1041.
38	YAMAUCHI N, KANKE Y, SAITO K, et al. Stromal expression of cancer-associated fibroblast-related molecules, versican and lumican, is strongly associated with worse relapse-free and overall survival times in patients with esophageal squamous cell carcinoma[J]. Oncol Lett, 2021, 21(6): 445.
39	DESJARDINS M, XIE J, GURLER H, et al. Versican regulates metastasis of epithelial ovarian carcinoma cells and spheroids[J]. J Ovarian Res, 2014, 7: 70.
40	DU W W, YANG W N, YEE A J. Roles of versican in cancer biology: tumorigenesis, progression and metastasis[J]. Histol Histopathol, 2013, 28(6): 701-713.
41	YANG B L, ZHANG Y, CAO L, et al. Cell adhesion and proliferation mediated through the G1 domain of versican[J]. J Cell Biochem, 1999, 72(2): 210-220.
42	XUE J P, CHEN J N, SHEN Q, et al. Addition of high molecular weight hyaluronic acid to fibroblast-like stromal cells modulates endogenous hyaluronic acid metabolism and enhances proteolytic processing and secretion of versican[J]. Cells, 2020, 9(7): 1681.
43	CATTARUZZA S, SCHIAPPACASSI M, KIMATA K, et al. The globular domains of PG-M/versican modulate the proliferation-apoptosis equilibrium and invasive capabilities of tumor cells[J]. FASEB J, 2004, 18(6): 779-781.
44	SHENG W, WANG G Z, WANG Y, et al. The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis[J]. Mol Biol Cell, 2005, 16(3): 1330-1340.
45	CHEN H, ZHAO Y, ZHANG J J, et al. Promoting effects of miR-135b on human multiple myeloma cells via regulation of the Wnt/β-catenin/versican signaling pathway[J]. Cytokine, 2021, 142: 155495.
46	ANG L C, ZHANG Y, CAO L, et al. Versican enhances locomotion of astrocytoma cells and reduces cell adhesion through its G1 domain[J]. J Neuropathol Exp Neurol, 1999, 58(6): 597-605.
47	YEUNG T L, LEUNG C S, WONG K K, et al. TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment[J]. Cancer Res, 2013, 73(16): 5016-5028.
48	杨迷玲, 杨金花, 王娜, 等. Versican与胃癌上皮-间质转化相关蛋白的表达及意义[J]. 医学研究杂志, 2022, 51(12): 69-74.
	YANG M L, YANG J H, WANG N, et al. Expression of versican and its relationship with epithelial-mesenchymal transition related proteins and clinical significance in gastric cancer[J]. Journal of Medical Research, 2022, 51(12): 69-74.
49	DU W W, FANG L, YANG W N, et al. The role of versican G3 domain in regulating breast cancer cell motility including effects on osteoblast cell growth and differentiation in vitro: evaluation towards understanding breast cancer cell bone metastasis[J]. BMC Cancer, 2012, 12: 341.
50	DOS REIS D C, DAMASCENO K A, DE CAMPOS C B, et al. Versican and tumor-associated macrophages promotes tumor progression and metastasis in canine and murine models of breast carcinoma[J]. Front Oncol, 2019, 9: 577.
51	ZHENG P S, WEN J P, ANG L C, et al. Versican/PG-M G3 domain promotes tumor growth and angiogenesis[J]. FASEB J, 2004, 18(6): 754-756.
52	LABROPOULOU V T, THEOCHARIS A D, RAVAZOULA P, et al. Versican but not decorin accumulation is related to metastatic potential and neovascularization in testicular germ cell tumours[J]. Histopathology, 2006, 49(6): 582-593.
53	EVANKO S P, POTTER-PERIGO S, BOLLYKY P L, et al. Hyaluronan and versican in the control of human T-lymphocyte adhesion and migration[J]. Matrix Biol, 2012, 31(2): 90-100.
54	POTTER-PERIGO S, JOHNSON P Y, EVANKO S P, et al. Polyinosine-polycytidylic acid stimulates versican accumulation in the extracellular matrix promoting monocyte adhesion[J]. Am J Respir Cell Mol Biol, 2010, 43(1): 109-120.
55	KAUR A, ECKER B L, DOUGLASS S M, et al. Remodeling of the collagen matrix in aging skin promotes melanoma metastasis and affects immune cell motility[J]. Cancer Discov, 2019, 9(1): 64-81.

[1]	徐文晖, 杨畅, 李瑞卿, 卞京, 李夏伊, 郑磊贞. 干扰素调节因子3促结直肠癌细胞增殖与侵袭相关探索[J]. 上海交通大学学报（医学版）, 2024, 44(3): 301-311.
[2]	王千懿, 冉欣悦, 张沛灵, 慈政, 雷东, 周广东. 软骨脱细胞基质/丝素蛋白活性支架的构建及其软骨组织工程研究[J]. 上海交通大学学报（医学版）, 2023, 43(7): 795-803.
[3]	魏兰懿, 薛晓川, 陈君君, 杨全军, 王梦月, 韩永龙. 骨肉瘤免疫微环境中肿瘤相关巨噬细胞及其靶向治疗的研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(5): 624-630.
[4]	王文博, 张方蓉, 石亭旺, 陈云丰. 恶性肿瘤荧光成像的研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(4): 474-479.
[5]	白龙, 夏翔, 曹晖, 张子臻. 腹腔灌洗液循环肿瘤DNA在预测胃肠道恶性肿瘤腹膜转移中应用的研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(12): 1554-1561.
[6]	唐雷, 徐迎春, 张凤春. 胶原蛋白在肿瘤发生和发展中的作用综述[J]. 上海交通大学学报（医学版）, 2023, 43(12): 1577-1584.
[7]	江永权, 戴利, 陈天宏, 王晶烁, 张奕, 李吉平. 不同术式治疗喉恶性肿瘤的效果及并发症分析[J]. 上海交通大学学报（医学版）, 2023, 43(11): 1430-1435.
[8]	吴瑞芳, 冯明, 孟健. 脂肪酸结合蛋白4在肥胖相关肿瘤中的作用综述[J]. 上海交通大学学报（医学版）, 2023, 43(10): 1311-1316.
[9]	马芳芳, 秦洁洁, 任灵杰, 唐笑梅, 刘佳, 施敏敏, 蒋玲曦. 基于水凝胶微球建立胰腺癌原代细胞的3D培养模型[J]. 上海交通大学学报（医学版）, 2023, 43(1): 79-87.
[10]	林家俞, 秦洁洁, 蒋玲曦. 肿瘤微环境中免疫细胞的代谢研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(8): 1122-1130.
[11]	王雨心, 孙瑞琪, 刘坚华, 何伟娜. 开发用于肿瘤微环境成像的pH敏感荧光探针[J]. 上海交通大学学报（医学版）, 2022, 42(7): 875-884.
[12]	李静威, 王俐文, 蒋玲曦, 詹茜, 陈皓, 沈柏用. 胰腺癌免疫抑制性肿瘤微环境研究综述[J]. 上海交通大学学报(医学版), 2021, 41(8): 1103-1108.
[13]	那迪娜·帕尔哈提null, 严妍, 车千纪, 罗菁, 刘鑫男, 李斌. 嵌合抗原受体T细胞疗法在胶质母细胞瘤中的应用与展望[J]. 上海交通大学学报(医学版), 2021, 41(7): 982-986.
[14]	鲁婷玮, 张建军, 陈万涛. 恶性肿瘤细胞来源的外泌体调控自然杀伤细胞活性的相关机制[J]. 上海交通大学学报(医学版), 2021, 41(5): 659-664.
[15]	孙潇智, 李爽, 金颖, 廖兵. 酶消化细胞团块法对人胚胎干细胞中OCT4与SOX2蛋白水平的影响[J]. 上海交通大学学报(医学版), 2021, 41(4): 413-420.